Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ENTA 
Enanta Pharmaceuticals Inc (ENTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ENTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.14
1 Year Target Price $19.14
| 2 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.19% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 328.35M USD | Price to earnings Ratio - | 1Y Target Price 19.14 |
Price to earnings Ratio - | 1Y Target Price 19.14 | ||
Volume (30-day avg) 6 | Beta 0.89 | 52 Weeks Range 4.09 - 15.34 | Updated Date 10/16/2025 |
52 Weeks Range 4.09 - 15.34 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -141.98% | Operating Margin (TTM) -103.16% |
Management Effectiveness
Return on Assets (TTM) -17.29% | Return on Equity (TTM) -80.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 141917944 | Price to Sales(TTM) 5.07 |
Enterprise Value 141917944 | Price to Sales(TTM) 5.07 | ||
Enterprise Value to Revenue 2.19 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 28852923 | Shares Floating 14835423 |
Shares Outstanding 28852923 | Shares Floating 14835423 | ||
Percent Insiders 5.09 | Percent Institutions 71.46 |
Upturn AI SWOT
Enanta Pharmaceuticals Inc
Company Overview
History and Background
Enanta Pharmaceuticals, Inc. was founded in 1995 and is based in Watertown, Massachusetts. It is a biotechnology company focused on researching, developing, and commercializing small molecule drugs for viral infections and liver diseases.
Core Business Areas
- Viral Infections: Research and development of antiviral therapies, including direct-acting antivirals (DAAs) for respiratory syncytial virus (RSV).
- Liver Diseases: Development of treatments for non-alcoholic steatohepatitis (NASH) and other liver-related conditions.
Leadership and Structure
Jay R. Luly serves as President and CEO. The company has a typical biotechnology organizational structure with teams focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Glecaprevir (partnered with AbbVie): Glecaprevir is a component of the HCV treatment MAVYRET/MAVIRET. Enanta receives royalties from AbbVie's sales. Market share for MAVYRET has diminished considerably since being launched due to other competitors having easier to manage treatment regiments. Competitors include Gilead Sciences and Merck.
- EDP-938 (RSV L-protein inhibitor): An investigational oral L-protein inhibitor for respiratory syncytial virus (RSV). Currently in clinical trials. Competitors include Pfizer (Abrysvo), GSK (Arexvy), and various other companies developing RSV therapies.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high-risk, high-reward research and development. Success depends on innovation, clinical trial outcomes, and regulatory approvals. The antiviral and liver disease markets are competitive and driven by unmet medical needs.
Positioning
Enanta Pharmaceuticals is a research-driven company focused on developing innovative therapies for viral infections and liver diseases. Its competitive advantage lies in its expertise in small molecule drug discovery and development.
Total Addressable Market (TAM)
The NASH and RSV markets are estimated to be in the billions of dollars. Enanta's potential market share depends on the success of its clinical trials and regulatory approvals for its pipeline candidates.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Expertise in small molecule drug discovery
- Partnership with AbbVie for HCV royalties
- Focus on unmet medical needs
Weaknesses
- Reliance on royalties from a single product (MAVYRET) which is declining
- High risk of clinical trial failures
- Cash Burn Rate
- Limited commercialization capabilities independently
Opportunities
- Successful development and approval of RSV and NASH drugs
- Expansion of pipeline through strategic collaborations
- Increased demand for effective antiviral and liver disease therapies
- Potential for breakthrough therapies with significant market impact
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and delays
- Patent expirations and generic entry
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GILD
- MRK
- PFE
- GSK
Competitive Landscape
Enanta faces intense competition from larger pharmaceutical companies with greater resources. Its success depends on its ability to innovate and execute its clinical development programs effectively.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been tied to MAVYRET royalties and advancements in its pipeline.
Future Projections: Future growth depends on the success of EDP-938 and other pipeline candidates. Analyst estimates vary based on clinical trial progress and regulatory expectations.
Recent Initiatives: Focusing on advancing its RSV and NASH programs, and exploring strategic collaborations.
Summary
Enanta Pharmaceuticals is a research-driven biotech company with expertise in small molecule drug discovery. The company's historical success was tied to royalties from HCV treatment MAVYRET, but faces declining revenue as competitors have taken market share. Future success depends on its pipeline candidates, especially EDP-938. Enanta has strengths in research and development, but its reliance on pipeline progress and competition from larger companies pose significant risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Public Financial Statements
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enanta Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2013-03-21 | President, CEO & Director Dr. Jay R. Luly Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.enanta.com |
Full time employees 131 | Website https://www.enanta.com | ||
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.